anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Solid organ transplantation is a risk predictor for virally-mediated anal squamous intraepithelial lesions and cancer (anal disease). Precancerous squamous intraepithelial lesions can be detected by screening, and treatment may prevent cancer progression. Screening recommendations are not well defined. We aim to define prevalence and describe risk predictors for anal disease in a large population of solid organ transplant recipients.
METHODS: Retrospective single-center cohort analysis included solid organ transplant recipients cared for between 2001 and 2022 (N = 15 362). The cohort of recipients who developed anal disease was compared with those who did not. Greedy propensity score matching was performed for organ-specific recipients, and time-to-event analysis for the development of anal disease was performed in those with genitourinary human papilloma virus (HPV) disease versus those without.
RESULTS: Prevalence of anal disease was 0.6% (cancer 0.2%). The average years from transplant to the diagnosis of anal disease was 11.67. Anal disease was more common in women (68.5% versus 31.5%, P  < 0.001), patients who had other HPV-related genitourinary diseases (40.4% versus 0.6%, P  < 0.001), who were of younger age at transplant (39.62 versus 46.58, P  < 0.001), and had increased years from transplant (17.06 versus 12.57, P  < 0.001). In multivariate analysis, the odds of anal disease increased by 4% each year posttransplant. History of genitourinary HPV disease (odds ratio 69.63) and female sex (odds ratio 1.96) were the most significant risk predictors for anal disease.
CONCLUSIONS: The prevalence of anal cancer among solid organ transplant recipients was equal to the general population (0.2%). Due to the low prevalence of overall disease, these data suggest that anal screenings in transplant recipients should be targeted to higher-risk subsets: female recipients farther out from transplant and patients with genitourinary HPV-related diseases.
Participants will start their quit attempts within 30 days of their enrollment into the study. They will select their target quit dates without regard for their MC. Participants will be receiving NRT and will have access to behavioral support for the following 6 weeks.
Participants received placebo matching setmelanotide once daily by SC injection from Days 1 to 16. Participants also received a single oral dose of 400 mg moxifloxacin on Day 10 and a single oral dose of placebo matching moxifloxacin on Day 16.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to obstetrics, and can be applied for prevention of severe forms of obstetrical pathology. Method includes preliminary dopplerometry of uterine-placental hemodynamics condition for pregnant women at 2 trimester of pregnancy. After that, infusion of magnesia in dose 30.0 ml is performed. One day after infusion repeated dopplerometry of uterine arteries is carried out and if the spasm of uterine vessel remains - donor of nitrogen oxide - nebilet in minimal dose in dose 2.5 mgx2 times per day is prescribed under control of AP and pulse. ^ EFFECT: invention application makes it possible to reduce number of pregnancy complications associated with severe form of obstetrical pathology and perinatal loss due to reduction of endothelial dysfunction severity and recovery of uterine-placental blood flow intensity without negative action on fetoplacental blood flow. ^ 2 tbl, 3 ex
The invention provides a traditional Chinese medicinal formula for treating chronic bronchitis. The traditional Chinese medicinal formula is prepared from the following medicinal raw materials, by weight, 20-25 parts of Astragalus membranaceus, 5-25 parts of Chinese yam, 3-20 parts of teasel root, 16-35 parts of fried millet sprout, 7-25 parts of Curculigo orchioides, 10-50 parts of Cornus officinalis, 3-16 parts of spine date seed, 5-18 parts of fritillaria, 7-25 parts of dried orange peel and 5-25 parts of radix rehmanniae preparata. The formula provided by the invention can fundamentally treat chronic bronchitis. During treatment period, infection of bacteria can be reduced effectively. Meanwhile, the formula has a remarkable treatment effect, and produces a desired effect after about 7 days. After treatment, chronic bronchitis will not recur.
The present invention relates to protein-based nanoparticles, synthesis of these nanoparticles and their use in cancer therapy for improving the stabilization and cellular uptake of MS1 peptide that specifically binds to and inhibits Mcl-1 protein. In the present invention, a novel fusion protein design has been realized to induce apoptosis in cancer cells. Said fusion protein consists of three parts. The first part is an antiapoptotic inhibitory cationic peptide (MS1 peptide) targeting the BH3 domain of the MCL-1 protein, the second part is a fluorescent protein, and the third part is a peptide containing the amino acid histidine. This engineered protein was expressed and successfully purified by using recombinant DNA technology. Self-assembled protein-based nanoparticles were obtained from the fusion protein produced with the present invention, and the characterization of the nanoparticles was performed. This protein was also encapsulated into PLGA- PBAE based hybrid polymeric nanoparticles and the characterization of the produced nanoparticles was performed. Nanoparticular systems produced by the present invention showed selective cytotoxic effect against cancer cell line with high MCL-1 expression compared to healthy cell line and induced apoptosis in these cells.
Poor measurement quality has set back the utility of anthropometry in defining childhood malnutrition, prompting calls for alternative measurement techniques. This study aimed to assess the reliability of anthropometric measurements using a digital height board in comparison to an analog height board in Namibian children under 5 years of age. A cross-sectional, descriptive study was conducted (n = 425) between the age of 6 and 59 months, using anthropometric measurements of weight, height and mid-upper arm circumference. Two trained enumerators each collected four height measurements of each child: two using an analog height board and two using a digi-board. The repeated height measurements between and within the enumerators were used to determine intra- and interobserver reliability. Reliability of the digi-board was assessed using the technical error of measurement (TEM), relative TEM (%TEM), intraclass correlation and a Bland-Altman analysis to assess the agreement between the two methods. In all these assessments, the analog height board was considered as the gold standard and used for comparison. The digi-board showed superiority to the analog height board in terms of reliability (analog TEM = 0.22, digi-board TEM = 0.16). Although the digi-board has potential to improve child anthropometry, further clinical and large survey studies are needed to validate the used of this tool in routine population-based surveys.
PURPOSE:To execute exact and sure discrimination without requiring specific skill by coloring carriers conjugated with antigens and antibodies with dyes having different hues, mixing the same and making visual discrimination from the change of the colors. CONSTITUTION:The antigens or antibodies or the carriers conjugated therewith or the diluted soln. of inspecting materials are colored with the dyes having the respectively different hues and are thereafter mixed. The apparent changes of the mixing ratios of the respective colored dyes changing with the generated antigen-antibody reaction are detected as the change of the colors and are visually discriminated. Glass beads, paper disk, etc. in addition to latex, gelative, etc. are used as the carrier. The diluting liquid in exemplified by a physiological saline, phosphoric acid buffer, etc., and the dyes are exemplified by 'Indocyanine Green', 'Coomasie Brilliant Blue', etc., of cyan dye.
Cosmetic use of at least one antagonistic agent of the neuropeptide Y (NPY) (I) comprising peptides or nonpeptide chemical molecules or an extract comprising e.g. extracts obtained by extraction of sponge Orina sp., Gray sp.or Gellius sp., extracts from fermentations of Aspergillus strains, and extracts obtained from Cynara scolymus, in a composition containing a medium, to improve the appearance of lips by increasing the volume and/or the natural color of lips, is claimed. Cosmetic use of at least one antagonistic agent of the neuropeptide Y (NPY) (I) comprising peptides or nonpeptide chemical molecules or an extract comprising extracts obtained by extraction of sponge Orina sp., Gray sp.or Gellius sp., extracts from fermentations of Aspergillus strains, extracts obtained from fermentation of Actinomycetaceae strains and extracts obtained from Cynara scolymus, in a composition containing a medium, to improve the appearance of lips by increasing the volume and/or the natural color of lips, is claimed. Independent claims are included for: (1) cosmetic process to plump up and/or providing natural color to lips comprising (a) applying a composition comprising at least one antagonistic agent of neuropeptide Y to the lips; and (2) set or kit for lip care comprising: (aa) a composition comprising a lipstick, liquid lip gloss, lip paste, lip pencil, lip balm or lip varnish; and (bb) a second composition comprising as active agent, at least one antagonist of neuropeptide Y. ACTIVITY : Dermatological; Vasotropic; Vasodilator. MECHANISM OF ACTION : Neuropeptide Y (NPY) antagonist.
Preterm birth is the leading cause of perinatal mortality and morbidity. In a recently completed trial of weekly injections of 17 alpha hydroxyprogesterone caproate (17P), the National Institute of Child Health and Human Development (NICHD) Maternal Fetal Medicine Units (MFMU) Network found the treatments significantly beneficial in the prevention of recurrent preterm birth. Other studies have shown that fish oil supplementation can reduce the risk for preterm birth. The purpose of this study is to determine whether Omega-3, a polyunsaturated fatty acid nutritional supplement, in addition to injections of 17P, further decreases the rate of preterm birth in women at risk.

This study is a randomized, double-masked clinical trial with two study arms: a daily supplement of Omega-3 capsules containing 800 mg of DHA and 1200 mg of EPA or a daily supplement of a matching placebo. All patients will also receive weekly injections of 17P. Eight hundred pregnant women with a history of previous preterm delivery will be recruited for this study. After successfully completing a compliance run-in, which can begin as early as 15 weeks gestation, patients will be randomized and begin treatment between 16 and 22 weeks gestation. They will remain on study drug until 36 week and 6 days or delivery, whichever occurs first. Blood will be drawn at randomization and at a monthly visit falling between 25-29 weeks of gestation to test for compliance, to analyze genetic polymorphisms and to determine whether Omega-3 affects the production of inflammatory cytokines.
OBJECTIVE: To review the association of surfactant protein-D with type 2 diabetes mellitus, infections, oxidative stress and inflammation, and the changes in oxidative stress markers in type 2 diabetes mellitus.
METHODS: The systematic review was conducted from April to September 2022, and comprised search on PubMed, Web of Sciences, Scopus, Science Direct and Google Scholar databases for relevant studies published in English language between January 1, 2000, and June 30, 2022. The search was updated in September 2022. After transferring literature to Mendeley, relevant data was extracted from the included studies. Quality assessment for eligible studies was done using Joanna Briggs Institute Critical Appraisal Checklist. Quality of evidences was assessed by using Grading of Recommendations Assessment, Development and Evaluation tool.
RESULTS: Of the 203 studies identified, 18(8.9%) were analysed; 16(89%) with humans and 2(11%) with animals as subjects There were 5 (31.25%) studies for SP-D, of which 4 (80%) studies reported lower surfactant protein-D in type 2 diabetes mellitus cases than controls. Its significant negative association with glycated haemoglobin was reported by 1(20%) study and 2(40%) studies with fasting blood glucose levels. Higher surfactant protein-D in type 2 diabetes mellitus cases and its positive association with glycated haemoglobin was reported by 1(20%) study. Recurrent infections were frequent in type 2 diabetes mellitus patients. Malondialdehyde level was higher and superoxide dismutase activity was lower in type 2 diabetes mellitus cases, reflecting oxidative stress. Animal studies also showed that reactive oxygen species generating from hypochlorous acid during oxidative stress promoted the formation of non-disulfide linkages in surfactant protein-D structure, resulting in its decreased functionality.
CONCLUSION: Surfactant protein-D, oxidative stress, inflammation and infections were found to be linked to each other for pathogenesis of infections in type 2 diabetes mellitus.
This study arm will only participate in part A of the study (Characterisation study) and thus will not receive the study drug. A maximum of 35 healthy volunteers will be included in this study arm.
The invention relates to a computer system (100) for the anonymization of personal data. The computer system comprises a control computer system (128), a provisioning computer system (128, 262) and at least one user computer system (160). The control computer system comprises a control software (140) for providing anonymized personal data to an analysis software (139). The analysis software comprises a plurality of different analysis functions (132-138). The provisioning computer system comprises a plurality of anonymization protocols (121) each associated with one of said plurality of different analysis functions (132-138). Each of the anonymization protocols is configured to select and anonymize personal data in a manner adapted to the one analysis functions associated with said analysis protocol. The user computer system comprises a data store (102) in which personal data (104-110) is stored and an anonymization software (114).The anonymization software is configured for:- receiving at least one anonymization protocol (120);for each of said at least one anonymization protocol:- selecting and anonymizing a subset of the personal data in accordance with said anonymizing protocol; and- transferring the anonymized subset and an identifier of the anonymization protocol to the control software.The control software is configured for:- receiving the at least one anonymized subset and the at least one identifier from said anonymizing software; and- providing the subset and the identifier to the analysis software for performing those analysis functions to which the anonymization protocol identified by the identifier is associated, on the subset.
Tumor neoantigen specific T cells will be infused intravenously into patients. The number of T cells will be more than 1.0E9.
Table 4. Description

Clobazam is a white or almost white, crystalline powder with a slightly bitter taste; is slightly soluble in water, sparingly soluble in ethanol, and freely soluble in methylene chloride. The melting range of clobazam is from 179ºC to 185ºC. The molecular formula is C 16H 13O 2N 2Cl and the molecular weight is 300.7. 

Clobazam Oral Suspension is available for oral administration as an off-white suspension containing clobazam at a concentration of 2.5 mg/mL. Inactive ingredients include citric acid anhydrous, disodium phosphate anhydrous, magnesium aluminum silicate, maltitol solution, methylparaben, polysorbate 80, propylene glycol, propylparaben, purified water, simethicone emulsion, sucralose, xanthan gum and artificial blueberry flavor.
Patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) and without obvious liver disease. Will have liver function blood tests and general health check ups. Then will have FibroScan performed. No liver biopsy will be performed in control patients.
All 10 patients included in the study will be neurosurgically implanted with the ABI. This is open label, not blinded. The implant is permanent, but can be switched off.
FIELD: medicine. SUBSTANCE: invention relates to method of enhancement of cytotoxicity of chemotherapeutic agent with respect to solid tumors exhibiting sensitivity in treatment with chemotherapeutic agent. Method involves administration of benzotriazine derivative to mammal bearing this tumor that enhances the cytotoxicity of chemotherapeutic agent being this administration is carried out 0.5-24 h before the latter agent. Invention relates to also the set used for treatment of patients bearing these tumors that contains chemotherapeutic agent and 1,2,4-benzo-triazine oxide taken at amount enhancing cytotoxicity of chemotherapeutic agent. EFFECT: broadened arsenal of agents used for treatment of solid tumors. 11 cl, 2 dwg, 19 ex
Compositions and methods for mitigating and preventing the effects of alcohol consumption are provided. A first composition can be ingested by an individual prior to or within six hours of alcohol consumption. A second composition can be ingested by the individual either at the onset of negative symptoms associated with alcohol consumption or the morning following alcohol consumption. The first and second compositions can be ingested individually, or in combination. When both the first and second composition are consumed, the first composition is to be consumed prior to the second composition, and both are to be consumed in a timely manner. Both compositions can be administered orally. The compositions can each be administered as a fluid solution. Only one serving of each composition is required to achieve the desired effects. Results are strengthened when both compositions are consumed in combination.
Cathepsin G (CTSG) plays an important role in the regulation of immune processes. Accumulated studies show that CTSG is involved in the onset and development of type 1 diabetes mellitus (T1DM). As the genetic background of T1DM varies widely among populations, we aimed to study the relationship between genetic polymorphisms in CTSG and T1DM susceptibility in Chinese populations. A total of 141 patients with T1DM and 200 healthy controls were enrolled in the study. Serum CTSG expression was detected using enzyme-linked immunosorbent assay (ELISA). Genotyping of two selected single nucleotide polymorphisms (SNPs) (rs2236742 and rs2070697) of CTSG was performed using PCR and Sanger sequencing. CTSG expression in patients with T1DM was significantly higher than in the control group. Alleles C and T of CTSG SNP rs2236742 were increased in T1DM. No significant associations were found for the SNP rs2070697. Our results indicate that the CTSG rs2236742 allele (C/T) is associated with T1DM in Chinese children and may serve as a new biomarker for predicting T1DM susceptibility.
FIELD: medicine, chemical-pharmaceutical industry. SUBSTANCE: raw is extracted for two stages. Firstly, raw is subjected for undischarge treatment into coaxial extraction chamber sizes of that are taken among the ratio: 4 >   > 3.5 where D is internal chamber diameter; d is current-carrier diameter. Raw impregnated with extractant is treated by pulse electric field of high intensity with value approximating to breakdown one that is produced by voltage impulse with duration 0.2 mcs and impulse number 350. Grist obtained after the first stage of treatment in common with extract is extracted three-fold for 1 h. Extracts are combined, concentrated under vacuum, product is precipitated and dried. EFFECT: enhanced purity of end product. 1 tbl, 1 dwg
Extranodal marginal zone lymphomas (eMZL) can occur in any organ and site of the body. Recent research has shown that they differ from organ to organ in terms of their mutational profile. In this study, we investigated a cohort of primary breast marginal zone lymphomas (PBMZL) to get a better insight into their morphologic and molecular profile. A cohort of 15 cases (14 female and 1 male) was characterized by immunohistochemistry (IHC) for 19 markers, fluorescence in situ hybridization (FISH), and high throughput sequencing (HTS) using a lymphoma panel comprising 172 genes. In addition, PCR for the specific detection of Borrelia spp. and metagenomics whole genome sequencing were performed for infectious agent profiling. Follicular colonization was observed in most cases, while lymphoepithelial lesions, though seen in many cases, were not striking. All 15 cases were negative for CD5, CD11c, and CD21 and positive for BCL2 and pan B-cell markers. There were no cases with BCL2 , BCL10 , IRF4 , MALT1 , or MYC translocation; only 1 had a BCL6 rearrangement. HTS highlighted TNFAIP3 (n=4), KMT2D (n=2), and SPEN (n=2) as the most frequently mutated genes. There were no Borrelia spp. , and no other pathogens detected in our cohort. One patient had a clinical history of erythema chronicum migrans affecting the same breast. PBMZL is a mutation-driven disease rather than fusion-driven. It exhibits mutations in genes encoding components affecting the NF-κB pathway, chromatin modifier-encoding genes, and NOTCH pathway-related genes. Its mutational profile shares similarities with ocular adnexal and nodal MZL.
Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity. Will be assigned to GEM Tool and a health coach.
Cyanocobalamin is a synthetic form of vitamin B12. The chemical name is 5,6-dimethyl-benzimidazolyl cyanocobamide. The cobalt content is 4.35%. The molecular formula is C63H88CoN14O14P, which corresponds to a molecular weight of 1355.38 and the following structural formula:

Figure 1. Cyanocobalamin Nasal Spray Chemical Structure 

Cyanocobalamin occurs as dark red crystals or orthorhombic needles or crystalline red powder. It is very hygroscopic in the anhydrous form, and sparingly to moderately soluble in water (1:80). Its pharmacologic activity is destroyed by heavy metals (iron) and strong oxidizing or reducing agents (vitamin C), but not by autoclaving for short periods of time (15-20 minutes) at 121°C. The vitamin B12 coenzymes are very unstable in light.

Cyanocobalamin Nasal Spray is a solution of cyanocobalamin, USP (vitamin B12) for administration as a spray to the nasal mucosa. Each unit dose device of Cyanocobalamin Nasal Spray contains 0.125 mL of a 500 mcg/0.1 mL solution of cyanocobalamin with benzalkonium chloride in purified water, citric acid, glycerin and sodium citrate. The spray solution has a pH between 4.5 and 5.5. Each spray delivers an average of 500 mcg of cyanocobalamin per actuation.
PROBLEM TO BE SOLVED: To obtain a new compound useful for a treating agent or a prophylactic agent for allergic diseases, parasitic infections diseases, autoimmune diseases such as systemic lupus erythematosus or the like. SOLUTION: A compound of formula I (R1 is a 2-6C alkyl, a 2-6C alkenyl or the like; R2 is H, a 1-6C alkyl or the like; R3 is H or a 1-6C alkyl; R4 to R7 are each H, OH or the like), for example, N-(2-aminoquinazolin-4-yl)-N- cyclohexylmethylamine. The compound of formula I is obtained, for example, by reacting a compound of formula II (e.g. 2-amino-4-chloroquinazoline) with a compound of formula III (e.g. cyclohexylmethylamine) in a solvent such as dimethylformamide at a temperature, for example, from room temperature to the boiling point of the solvent. The compound is useful as an immunomodulator which suppresses the immune response of type 2 helper T cell-side and stimulates that of type 1 helper T cell-side.